Biosimilars Council submits comments to FDA for promotional labeling and advertising considerations
Today, on behalf of its members, the Biosimilars Council submitted comments to the FDA on draft guidance that discusses considerations for presenting data and information about reference products or biosimilar products in promotional communications.